Novacyt S.A. (LON:NCYT – Get Free Report)’s stock price fell 2.6% during trading on Wednesday . The company traded as low as GBX 56 ($0.73) and last traded at GBX 57.30 ($0.74). 33,852 shares changed hands during trading, a decline of 94% from the average session volume of 572,561 shares. The stock had previously closed at GBX 58.80 ($0.76).
Novacyt Trading Up 1.2 %
The company has a current ratio of 4.04, a quick ratio of 4.46 and a debt-to-equity ratio of 18.67. The company has a market cap of £40.26 million, a price-to-earnings ratio of -109.62 and a beta of -1.86. The firm has a 50-day moving average price of GBX 71.73 and a 200 day moving average price of GBX 61.50.
Novacyt Company Profile
Novacyt SA, together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments.
Featured Articles
- Five stocks we like better than Novacyt
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Growth Stocks and Investing in Them
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Manufacturing Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
